{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T12:47:11Z","timestamp":1780836431454,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01538-9","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:49:34Z","timestamp":1750686574000},"page":"1231-1243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetics and Exposure\u2013Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0977-6921","authenticated-orcid":false,"given":"Yuwen","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Guiastrennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4268-8394","authenticated-orcid":false,"given":"Miriam","family":"Stuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2706-8913","authenticated-orcid":false,"given":"Robert C.","family":"Penland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-7810","authenticated-orcid":false,"given":"Pradeep B.","family":"Lukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"1538_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157:790\u2013804. https:\/\/doi.org\/10.1016\/j.chest.2019.10.053.","journal-title":"Chest"},{"key":"1538_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","volume":"76","author":"DJ Jackson","year":"2021","unstructured":"Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76:220\u20137. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215168.","journal-title":"Thorax"},{"key":"1538_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","volume":"160","author":"LG Heaney","year":"2021","unstructured":"Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160:814\u201330. https:\/\/doi.org\/10.1016\/j.chest.2021.04.013.","journal-title":"Chest"},{"key":"1538_CR4","doi-asserted-by":"publisher","first-page":"00024-2015","DOI":"10.1183\/23120541.00024-2015","volume":"1","author":"JC de Groot","year":"2015","unstructured":"de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:00024-2015. https:\/\/doi.org\/10.1183\/23120541.00024-2015.","journal-title":"ERJ Open Res."},{"key":"1538_CR5","doi-asserted-by":"publisher","first-page":"00100-2015","DOI":"10.1183\/23120541.00100-2015","volume":"2","author":"JC de Groot","year":"2016","unstructured":"de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016;2:00100-2015. https:\/\/doi.org\/10.1183\/23120541.00100-2015.","journal-title":"ERJ Open Res."},{"key":"1538_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3390\/biomedicines10092181","volume":"10","author":"A Vatrella","year":"2022","unstructured":"Vatrella A, Maglio A, Pelaia C, et al. Eosinophilic inflammation: an appealing target for pharmacologic treatments in severe asthma. Biomedicines. 2022;10:2181. https:\/\/doi.org\/10.3390\/biomedicines10092181.","journal-title":"Biomedicines."},{"key":"1538_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2010.04.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1538_CR8","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448\u201358. https:\/\/doi.org\/10.1056\/NEJMoa1703501.","journal-title":"N Engl J Med"},{"key":"1538_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/s2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9:260\u201374. https:\/\/doi.org\/10.1016\/s2213-2600(20)30414-8.","journal-title":"Lancet Respir Med"},{"key":"1538_CR10","doi-asserted-by":"publisher","first-page":"2301521","DOI":"10.1183\/13993003.01521-2023","volume":"64","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Pelaia G, Emmanuel B, et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024;64:2301521. https:\/\/doi.org\/10.1183\/13993003.01521-2023.","journal-title":"Eur Respir J"},{"key":"1538_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/JAA.S227170","volume":"12","author":"JM FitzGerald","year":"2019","unstructured":"FitzGerald JM, Bleecker ER, Bourdin A, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401\u201313. https:\/\/doi.org\/10.2147\/JAA.S227170.","journal-title":"J Asthma Allergy."},{"key":"1538_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","volume":"10","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10:47\u201358. https:\/\/doi.org\/10.1016\/S2213-2600(21)00352-0.","journal-title":"Lancet Respir Med"},{"key":"1538_CR13","doi-asserted-by":"publisher","first-page":"2103226","DOI":"10.1183\/13993003.03226-2021","volume":"60","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Gurnell M, Heaney LG, et al. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study. Eur Respir J. 2022;60:2103226. https:\/\/doi.org\/10.1183\/13993003.03226-2021.","journal-title":"Eur Respir J"},{"key":"1538_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-019-00738-4","volume":"58","author":"L Yan","year":"2019","unstructured":"Yan L, Wang B, Chia YL, et al. Population pharmacokinetic modeling of benralizumab in adult and adolescent patients with asthma. Clin Pharmacokinet. 2019;58:943\u201358. https:\/\/doi.org\/10.1007\/s40262-019-00738-4.","journal-title":"Clin Pharmacokinet"},{"key":"1538_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/cpt.1371","volume":"106","author":"YL Chia","year":"2019","unstructured":"Chia YL, Yan L, Yu B, et al. Relationship between benralizumab exposure and efficacy for patients with severe eosinophilic asthma. Clin Pharmacol Ther. 2019;106:383\u201390. https:\/\/doi.org\/10.1002\/cpt.1371.","journal-title":"Clin Pharmacol Ther"},{"key":"1538_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/02770903.2019.1663428","volume":"58","author":"UJ Martin","year":"2021","unstructured":"Martin UJ, Fuhr R, Forte P, et al. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J Asthma. 2021;58:93\u2013101. https:\/\/doi.org\/10.1080\/02770903.2019.1663428.","journal-title":"J Asthma"},{"key":"1538_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DDDT.S392155","volume":"17","author":"TT Cheung","year":"2023","unstructured":"Cheung TT, Mai TH, Chia YL, et al. Safety, tolerability, and pharmacokinetics of benralizumab: a phase 1, randomized, single-blind study of healthy Chinese participants. Drug Des Devel Ther. 2023;17:209\u201318. https:\/\/doi.org\/10.2147\/DDDT.S392155.","journal-title":"Drug Des Devel Ther."},{"key":"1538_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107611","volume":"8","author":"K Lai","year":"2024","unstructured":"Lai K, Sun D, Dai R, et al. Benralizumab efficacy and safety in severe asthma: a randomized trial in Asia. Respir Med. 2024;8: 107611. https:\/\/doi.org\/10.1016\/j.rmed.2024.107611.","journal-title":"Respir Med"},{"key":"1538_CR19","doi-asserted-by":"publisher","unstructured":"Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society\/European Respiratory Society statement. Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59\u201399. https:\/\/doi.org\/10.1164\/rccm.200801-060ST.","DOI":"10.1164\/rccm.200801-060ST"},{"key":"1538_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","volume":"125","author":"WW Busse","year":"2010","unstructured":"Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125:1237\u201344.e2. https:\/\/doi.org\/10.1016\/j.jaci.2010.04.005.","journal-title":"J Allergy Clin Immunol"},{"key":"1538_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1538_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059569","volume":"8","author":"XN Zong","year":"2013","unstructured":"Zong XN, Li H. Construction of a new growth references for China based on urban Chinese children: comparison with the WHO growth standards. PLoS ONE. 2013;8: e59569. https:\/\/doi.org\/10.1371\/journal.pone.0059569.","journal-title":"PLoS ONE"},{"key":"1538_CR23","unstructured":"European Medicines Agency. ICH guideline E11A on pediatric extrapolation - scientific guideline. London; EMA; 2022. https:\/\/www.ema.europa.eu\/en\/ich-guideline-e11a-pediatric-extrapolation-scientific-guideline. Accessed 19 September 2024."},{"key":"1538_CR24","unstructured":"US Food and Drug Administration. General clinical pharmacology considerations for pediatric studies of drugs, including biological products. Rockville (MD): US FDA; 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products. Accessed 19 September 2024."},{"key":"1538_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14092","volume":"35","author":"HJ Wedner","year":"2024","unstructured":"Wedner HJ, Fujisawa T, Guilbert TW, et al. Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study). Pediatr Allergy Immunol. 2024;35: e14092. https:\/\/doi.org\/10.1111\/pai.14092.","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01538-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01538-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01538-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:42:15Z","timestamp":1752594135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01538-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01538-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YJ, YY, WZ, YZ, PB, MJ, RCP, and PBL are employees of, and may hold stock in, AstraZeneca. JD was an employee of, and may hold stock in, AstraZeneca. BG and MS were employees of IntiQuan A.G. at the time of the analysis and received funding from AstraZeneca to conduct the modeling and simulation analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Prior to the initiation of the 12 clinical studies, local institutional review boards reviewed the study protocols and patient consent documents and provided written approvals. All clinical studies were in accordance with the ethical standards of the institutional and\/or national research committee, were conducted in accordance with the principles of the Declaration of Helsinki, and were consistent with the International Conference on Harmonization Guidance for Good Clinical Practice and applicable regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at . Data for studies directly listed on Vivli can be requested through Vivli at . Data for studies not listed on Vivli could be requested through Vivli at . The AstraZeneca Vivli member page also outlines further details: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study design and data interpretation, drafted the manuscript, or revised it critically for important intellectual content, and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}